Eva Ciruelos
About
Eva Ciruelos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Eva Ciruelos has authored 76 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 60 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Eva Ciruelos's work include Advanced Breast Cancer Therapies (58 papers), Cancer Treatment and Pharmacology (39 papers) and HER2/EGFR in Cancer Research (28 papers). Eva Ciruelos is often cited by papers focused on Advanced Breast Cancer Therapies (58 papers), Cancer Treatment and Pharmacology (39 papers) and HER2/EGFR in Cancer Research (28 papers). Eva Ciruelos collaborates with scholars based in Spain, United States and France. Eva Ciruelos's co-authors include Dejan Juric, Hope S. Rugo, Mario Campone, Sibylle Loibl, Fabrice André, Pierfranco Conté, Hiroji Iwata, Kenichi Inoue, Gábor Rubovszky and Ingrid A. Mayer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Eva Ciruelos
70 papers receiving 2.4k citations
Hit Papers
Peers
Eva Ciruelos
Katarína Petráková Czechia
Ben O’Leary United Kingdom
Yuqiu Jiang United States
Ilenia Migliaccio Italy
Celine Wilke United States
Mafalda Oliveira Spain
Gábor Rubovszky Hungary
Mónica Arnedos France
C. Giorgetti United States
Amrita Desai United States
Citations per year, relative to Eva Ciruelos Eva Ciruelos (= 1×)
peers
Katarína Petráková
Countries citing papers authored by Eva Ciruelos
Since
Specialization
Citations
This map shows the geographic impact of Eva Ciruelos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Ciruelos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Ciruelos more than expected).
Fields of papers citing papers by Eva Ciruelos
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eva Ciruelos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Ciruelos. The network helps show where Eva Ciruelos may publish in the future.
Co-authorship network of co-authors of Eva Ciruelos
This figure shows the co-authorship network connecting the top 25 collaborators of Eva Ciruelos. A scholar is included among the top collaborators of Eva Ciruelos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Ciruelos. Eva Ciruelos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tolosa, Pablo, et al.. (2025). Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2– breast cancer. Med. 6(9). 100781–100781.
2.
Sánchez-Bayona, Rodrigo, et al.. (2025). Oral SERDs: Transforming the treatment of advanced breast cancer—Insights from EMBER-3. Med. 6(2). 100602–100602.
3.
Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008.
4.
Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.
5.
Conté, Pierfranco, Eva Ciruelos, Giuseppe Curigliano, et al.. (2024). “Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper”. The Breast. 76. 103742–103742.
6.
Bartsch, Rupert, David Cameron, Eva Ciruelos, et al.. (2024). Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer. Cancer Treatment Reviews. 132. 102853–102853.
7.
Neven, Patrick, Neil Stahl, María Vidal, et al.. (2023). 273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2. Annals of Oncology. 34. S292–S293.
8.
Rugo, Hope S., Florence Lerebours, Eva Ciruelos, et al.. (2021). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncology. 22(4). 489–498.
9.
Ciruelos, Eva, Javier Cortés, Sònia Pernas, et al.. (2021). 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype. Annals of Oncology. 32. S77–S77.
10.
Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.
11.
André, Fabrice, Eva Ciruelos, Dejan Juric, et al.. (2020). LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Annals of Oncology. 31. S1150–S1151.
12.
Oliveira, Mafalda, Patricia Villagrasa, Eva Ciruelos, et al.. (2020). 351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER). Annals of Oncology. 31. S389–S389.
13.
Hurvitz, Sara A., Stephen Chia, Eva Ciruelos, et al.. (2020). 352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC). Annals of Oncology. 31. S389–S390.
14.
André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940.
15.
Ciérvide, R., Á. Montero, Estela Vega, et al.. (2019). Neoadjuvant Chemoradiation for Unfavourable Breast Cancer Patients: A Prospective Cohort Study. Journal of Clinical Trials. 9(3). 1–7.
16.
André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2018). Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Annals of Oncology. 29. viii709–viii709.
17.
Prat, Aleix, Mafalda Oliveira, Lorena de la Peña, et al.. (2017). SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer. Annals of Oncology. 28. v106–v107.
18.
Albanell, Joan, et al.. (2016). Estimated Costs of Locoregional and Metastatic Recurrences in Patients with HER2+ Breast Cancer in Spain. Value in Health. 19(7). A729–A729.
19.
André, Fabrice, Bella Kaufman, Dejan Juric, et al.. (2016). A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1). Annals of Oncology. 27. vi98–vi98.
20.
Leo, Angelo Di, Eva Ciruelos, Wolfgang Janni, et al.. (2015). BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.. Journal of Clinical Oncology. 33.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katarína Petráková Breakdown of academic impact, for papers by Ben O’Leary Breakdown of academic impact, for papers by Yuqiu Jiang Breakdown of academic impact, for papers by Ilenia Migliaccio Breakdown of academic impact, for papers by Celine Wilke Breakdown of academic impact, for papers by Mafalda Oliveira Breakdown of academic impact, for papers by Gábor Rubovszky Breakdown of academic impact, for papers by Mónica Arnedos Breakdown of academic impact, for papers by C. Giorgetti Breakdown of academic impact, for papers by Amrita Desai